摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(6-溴-2,3-二氯苯基)-1,3-二氧戊环 | 162271-15-0

中文名称
2-(6-溴-2,3-二氯苯基)-1,3-二氧戊环
中文别名
——
英文名称
2-bromo-4-(1,3-dioxolan-2-yl)phenol
英文别名
——
2-(6-溴-2,3-二氯苯基)-1,3-二氧戊环化学式
CAS
162271-15-0
化学式
C9H9BrO3
mdl
——
分子量
245.073
InChiKey
WWWAJAPPWHAJOK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    315.3±42.0 °C(Predicted)
  • 密度:
    1.638±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    38.7
  • 氢给体数:
    1
  • 氢受体数:
    3

SDS

SDS:608ec090255568255f0748b2c36c25ad
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    参考文献:
    名称:
    Bioactive prenylated phenyl derivatives derived from marine natural products: novel scaffolds for the design of BACE inhibitors
    摘要:
    生物测定引导分离了海绵 sp.中的活性提取物,导致了烯基化苯基衍生物的分离、生化特性鉴定和生物活性化学计划的开发。
    DOI:
    10.1039/c3md00236e
  • 作为产物:
    描述:
    3-溴-4-羟基苯甲醛乙二醇对甲苯磺酸 作用下, 以 甲苯 为溶剂, 以74%的产率得到2-(6-溴-2,3-二氯苯基)-1,3-二氧戊环
    参考文献:
    名称:
    通过Si-Si键激活将两个硅原子直接同位加成至C≡C三键:获得反应性二烯丙基化烯烃
    摘要:
    炔烃的催化分子内silapalladation可提供高收率和立体选择性地合成具有不同化学结构和大小的合成二甲硅烷基杂环。当将其应用于甲硅烷基醚时,该反应会导致乙烯基硅烷醇经过铑催化加成到活化烯烃中,从而根据反应条件提供oxa-Heck或oxa-Michael产物。
    DOI:
    10.1002/anie.201611719
点击查看最新优质反应信息

文献信息

  • Synthesis and Biological Evaluation of (±)-Abyssinone II and Its Analogues as Aromatase Inhibitors for Chemoprevention of Breast Cancer
    作者:Arup Maiti、Muriel Cuendet、Vicki L. Croy、Denise C. Endringer、John M. Pezzuto、Mark Cushman
    DOI:10.1021/jm070109i
    日期:2007.6.1
    An efficient and economical synthesis of the naturally occurring aromatase inhibitor abyssinone II was performed. The synthesis features an optimized aromatic prenylation reaction in which an arylcopper intermediate is reacted with prenyl bromide to afford a key intermediate that was converted to a prenylated aromatic aldehyde. Condensation of the aldehyde with an o-hydroxyacetophenone under Claisen-Schmidt
    进行了自然产生的芳香化酶抑制剂阿比西酮II的高效经济合成。该合成具有优化的芳族烯丙基化反应,其中芳基铜中间体与异戊烯基溴反应生成关键中间体,该中间体被转化为戊烯基化的芳族醛。在克莱森-施密特条件下,醛与邻羟基苯乙酮缩合得到查尔酮,该查尔酮在乙酸钠存在下在回流的乙醇中脱保护并环化,得到(+/-)-阿比西酮II。合成被证明是足够通用的,以提供一系列被评估为芳香化酶抑制剂的阿比西酮II衍生物。(+/-)-Abyssinone II的4'-羟基甲基化导致芳香化酶抑制活性显着提高,7-羟基的甲基化和异戊二烯基侧链的去除导致活性的进一步降低。这些结构变化的结果是,该系列中最活跃的黄烷酮的效力比(+/-)-阿比西酮II(IC50 40.95 microM)强20倍。
  • [EN] PHENYL-PRENYL DERIVATIVES, OF MARINE AND SYNTHETIC ORIGIN, FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS<br/>[FR] DÉRIVÉS DE PHÉNYLE-PRÉNYLE D'ORIGINE MARINE ET SYNTHÉTIQUE, DESTINÉS AU TRAITEMENT DE MALADIES OU TROUBLES COGNITIFS, NEURODÉGÉNÉRATIFS OU NEURONAUX
    申请人:NOSCIRA SA
    公开号:WO2009098287A1
    公开(公告)日:2009-08-13
    The present invention is related to a family of phenyl-prenyl derivatives of formula (I), and to their use in the treatment of cognitive, neurodegenerative or neuronal diseases or disorders, such as Alzheimer's disease or Parkinson's Disease. The present invention also relates to pharmaceutical compositions comprising the same. Further, the present invention is directed to the compounds of formula (I) for medical use, particularly for the use for the treatment and/or prevention of a cognitive, neurodegenerative or neuronal disease or disorder, and to the use of the compounds in the manufacture of a medicament for the treatment and/or prevention of a cognitive, neurodegenerative or neuronal disease or disorder.
    本发明涉及一类具有式(I)的苯基-烯丙基衍生物,以及它们在治疗认知、神经退行性或神经疾病或障碍,如阿尔茨海默病或帕金森病中的用途。本发明还涉及包含相同化合物的药物组合物。此外,本发明针对式(I)的化合物用于医疗用途,特别是用于治疗和/或预防认知、神经退行性或神经疾病或障碍,并且用于制造用于治疗和/或预防认知、神经退行性或神经疾病或障碍的药物的化合物。
  • Enantioselective Synthesis of Boron-Substituted Quaternary Carbon Stereogenic Centers through NHC-Catalyzed Conjugate Additions of (Pinacolato)boron Units to Enones
    作者:Suttipol Radomkit、Amir H. Hoveyda
    DOI:10.1002/anie.201309982
    日期:2014.3.24
    base catalyzed enantioselective boryl conjugate additions (BCAs) that generate products containing boron‐substituted quaternary carbon stereogenic centers are disclosed. Reactions are performed in the presence of 1.0–5.0 mol % of a readily accessible chiral accessible N‐heterocyclic carbene (NHC) and commercially available bis(pinacolato)diboron; cyclic or linear α,β‐unsaturated ketones can be used and
    公开了路易斯碱催化的对映选择性硼基共轭加成 (BCA) 的第一个例子,其产生包含硼取代的季碳立体中心的产物。反应在 1.0–5.0 mol% 的易于获得的手性可接近的 N-杂环卡宾 (NHC) 和市售的双(频哪醇)二硼存在下进行;可以使用环状或线性 α,β-不饱和酮,并且不需要严格排除空气或水分。以 63–95% 的产率和 91:9 至 >99:1 的对映体比率 (er) 获得所需产物。NHC 催化方法的特殊效用在天然产物抗真菌 (-)-crassinervic 酸的对映选择性合成的背景下得到证明。
  • CHEMOTHERAPEUTIC FLAVONOIDS, AND SYNTHESES THEREOF
    申请人:Cushman Mark S.
    公开号:US20100099755A1
    公开(公告)日:2010-04-22
    Substituted flavonoid compounds, and pharmaceutical formulations of flavonoid compounds are described. Also described are processes for preparing flavonid compounds, as are methods for treating cancer in mammals using the described flavonoid compounds or pharmaceutical formulations thereof.
    本文描述了替代黄酮类化合物和黄酮类化合物的药物配方。还描述了制备黄酮类化合物的过程,以及使用所述黄酮类化合物或其药物配方治疗哺乳动物癌症的方法。
  • PHENYL-PRENYL DERIVATIVES, OF MARINE AND SYNTHETIC ORIGIN, FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS
    申请人:Lopez Ogalla Javier
    公开号:US20110092591A1
    公开(公告)日:2011-04-21
    The present invention is related to a family of phenyl-prenyl derivatives of formula (I), and to their use in the treatment of cognitive, neurodegenerative or neuronal diseases or disorders, such as Alzheimer's disease or Parkinson's Disease. The present invention also relates to pharmaceutical compositions comprising the same. Further, the present invention is directed to the compounds of formula (I) for medical use, particularly for the use for the treatment and/or prevention of a cognitive, neurodegenerative or neuronal disease or disorder, and to the use of the compounds in the manufacture of a medicament for the treatment and/or prevention of a cognitive, neurodegenerative or neuronal disease or disorder.
    本发明涉及一类公式(I)的苯基-异戊烯基衍生物家族,以及它们在治疗认知、神经退行性或神经性疾病或疾病方面的用途,例如阿尔茨海默病或帕金森病。本发明还涉及包含这些化合物的制药组合物。此外,本发明针对公式(I)的化合物用于医疗用途,特别是用于治疗和/或预防认知、神经退行性或神经性疾病或疾病的用途,以及将这些化合物用于制造治疗和/或预防认知、神经退行性或神经性疾病或疾病的药物。
查看更多